Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBITDA: 2012-2024

Historic EBITDA for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to -$111.7 million.

  • Coherus Oncology's EBITDA rose 5.38% to -$44.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.7 million, marking a year-over-year increase of 58.48%. This contributed to the annual value of -$111.7 million for FY2024, which is 45.05% up from last year.
  • Per Coherus Oncology's latest filing, its EBITDA stood at -$111.7 million for FY2024, which was up 45.05% from -$203.2 million recorded in FY2023.
  • Over the past 5 years, Coherus Oncology's EBITDA peaked at $156.3 million during FY2020, and registered a low of -$263.9 million during FY2021.
  • Its 3-year average for EBITDA is -$190.6 million, with a median of -$203.2 million in 2023.
  • As far as peak fluctuations go, Coherus Oncology's EBITDA soared by 45.05% in 2020, and later tumbled by 268.79% in 2021.
  • Coherus Oncology's EBITDA (Yearly) stood at $156.3 million in 2020, then crashed by 268.79% to -$263.9 million in 2021, then increased by 2.64% to -$256.9 million in 2022, then increased by 20.90% to -$203.2 million in 2023, then spiked by 45.05% to -$111.7 million in 2024.